SRC and obesity due to melanocortin 4 receptor deficiency: Specifically, in adult metabolic disorders such as diabetes, cancer, or obesity, our findings here suggest that drugs that target mitochondrial SRC [64,65,66,67] could hold promise as therapeutic potential and might warrant further study for their ability to alter ATP levels and restore the BHI ratio to physiological levels.